Arena Pharmaceuticals, Inc. Selling, General and Administrative Expense
Arena Pharmaceuticals, Inc. reported Selling, General and Administrative Expense of $126.21 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2022-02-23
- Arena Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2021-12-31 was $34.51M, a 1.12% decline year-over-year.
- Arena Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2021-09-30 was $30.30M, a 59.48% increase year-over-year.
- Arena Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2021-06-30 was $31.94M, a 39.61% increase year-over-year.
- Arena Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2021-03-31 was $29.46M, a 11.41% increase year-over-year.
- Arena Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2021 was $126.21M, a 22.27% increase from fiscal 2020.
- Arena Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2020 was $103.22M, a 32.99% increase from fiscal 2019.
- Arena Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2019 was $77.62M, a 71.50% increase from fiscal 2018.
- Arena Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2018 was $45.26M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $34.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $64.81M derived: sum of 2 quarters · filed 2022-02-23 | $96.75M derived: sum of 3 quarters · filed 2022-02-23 | $126.21M 10-K · filed 2022-02-23 |
| 2021-09-30 | $30.30M 10-Q · filed 2021-11-04 | $62.24M derived: sum of 2 quarters · filed 2021-11-04 | $91.70M 10-Q · filed 2021-11-04 | $126.60M derived: sum of 4 quarters · filed 2022-02-23 |
| 2021-06-30 | $31.94M 10-Q · filed 2021-08-05 | $61.40M 10-Q · filed 2021-08-05 | $96.29M derived: sum of 3 quarters · filed 2022-02-23 | $115.30M derived: sum of 4 quarters · filed 2022-02-23 |
| 2021-03-31 | $29.46M 10-Q · filed 2021-05-05 | $64.36M derived: sum of 2 quarters · filed 2022-02-23 | $83.36M derived: sum of 3 quarters · filed 2022-02-23 | $106.23M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-12-31 | $34.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $53.90M derived: sum of 2 quarters · filed 2022-02-23 | $76.78M derived: sum of 3 quarters · filed 2022-02-23 | $103.22M 10-K · filed 2022-02-23 |
| 2020-09-30 | $19.00M 10-Q · filed 2021-11-04 | $41.88M derived: sum of 2 quarters · filed 2021-11-04 | $68.32M 10-Q · filed 2021-11-04 | $90.56M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $22.88M 10-Q · filed 2021-08-05 | $49.32M 10-Q · filed 2021-08-05 | $71.56M derived: sum of 3 quarters · filed 2022-02-23 | $91.99M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $26.44M 10-Q · filed 2021-05-05 | $48.69M derived: sum of 2 quarters · filed 2022-02-23 | $69.11M derived: sum of 3 quarters · filed 2022-02-23 | |
| 2019-12-31 | $22.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $42.67M derived: sum of 2 quarters · filed 2022-02-23 | $77.62M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $20.43M 10-Q · filed 2020-11-09 | $55.37M 10-Q · filed 2020-11-09 | ||
| 2018-12-31 | $45.26M 10-K · filed 2021-02-23 |